Unknown PHASE1/PHASE2 INTERVENTIONAL NCT04271163

Transcranial Electromagnetic Treatment (TEMT) Against Alzheimer's Disease

A Phase I Study to Evaluate the Safety and Efficacy of Transcranial Electromagnetic Treatment (TEMT) for the Treatment of Alzheimer's Disease: Extension Study II

Sponsor: Axiom Clinical Research of Florida

Conditions Alzheimer's Disease

Interventions MemorEM

Updated 5 times since 2020 Last updated: Feb 13, 2020 Started: Feb 10, 2020 Primary completion: Feb 28, 2021 Completion: Mar 31, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Alzheimer's Disease and is currently ongoing. Axiom Clinical Research of Florida leads this study, which shows 5 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Mar 2022 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2

Status: Active Not Recruiting → Unknown Status
Jan 2021 — Mar 2022 [monthly]

Active Not Recruiting PHASE1_PHASE2
Mar 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE1_PHASE2

First recorded

Feb 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Axiom Clinical Research of Florida
Invicro, Boston
Left Coast Engineering
MegaNano Biotech
NeuroEM Therapeutics, Inc.

Data source: NeuroEM Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tampa, United States